Stimulating PD-1???negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival1
- 1 September 2003
- journal article
- immunobiology
- Published by Wolters Kluwer Health in Transplantation
- Vol. 76 (6) , 994-999
- https://doi.org/10.1097/01.tp.0000085010.39567.fb
Abstract
Background. A balanced network of positive and negative T-cell co-stimulatory signals is important in regulating T-cell activation. Blocking CD28, CD154 (CD40L), or both co-stimulatory molecules has been efficacious in preventing acute allograft rejection in certain but not all transplantation models. In the present study, the authors tested the hypothesis that stimulating programmed death 1 (PD-1)–triggered negative signals concurrent with blocking CD154 co-stimulatory signals would facilitate islet allograft tolerance. Methods. The authors used a dimeric PD-L1 immunoglobulin (Ig) fusion protein to stimulate the inhibitory receptor PD-1, and a monoclonal antibody to block CD154. The effects of PD-1 engagement and CD154 blockade on lymphocyte activation were determined by cell proliferation, flow cytometry, and a model of islet transplantation. Results. PD-L1Ig inhibited the proliferation of both CD4+ and CD8+ T cells stimulated by anti-CD3. The inhibitory effect of PD-L1Ig was enhanced by concurrent blockade of CD154 co-stimulatory signals, as demonstrated by T-cell proliferation and expression of cell surface activation markers. PD-L1Ig and anti-CD154 also synergistically blocked the activation and maturation of antigen-presenting cells. In an islet transplantation model, treatment of recipient C57BL/6 (H-2b) mice with PD-L1Ig and anti-CD154 induced long-term survival of DBA/2 (H-2d) islet allografts, whereas treatment with each reagent alone failed to prevent islet allograft rejection. Conclusions. These results suggest that engaging the negative receptor PD-1 exhibits critical immunoregulatory effects in the allograft response, and blocking positive co-stimulatory molecules with active delivery of inhibitory signals may represent a novel therapeutic strategy in transplantation.Keywords
This publication has 24 references indexed in Scilit:
- Cutting Edge: Targeted Ligation of CTLA-4 In Vivo by Membrane-Bound Anti-CTLA-4 Antibody Prevents Rejection of Allogeneic CellsThe Journal of Immunology, 2002
- PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosineProceedings of the National Academy of Sciences, 2001
- PD-1: an inhibitory immunoreceptor involved in peripheral toleranceTrends in Immunology, 2001
- PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology, 2001
- Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient MiceScience, 2001
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying ImmunoreceptorImmunity, 1999
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInternational Immunology, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lgScience, 1992